breast cancer C50
Conditions
Interventions
Group 1: Patients receive a digital home health care system for remote monitoring of side effects under CDK4/6 inhibitor therapy
Sponsors
Frauenklinik des Uniklinikums Erlangen
Eligibility
Sex/Gender
All
Age
22 Years to No maximum
Inclusion criteria
Inclusion criteria: CDK4/6 cohort: - Indication for treatment with a CDK4/6 inhibitor as part of routine clinical practice - Treatment with a CDK4/6 inhibitor independent of the therapy cycle - Signed consent as part of the study Control cohort - Diagnosed cancer within the last five years - Signed consent within the scope of the study
Exclusion criteria
Exclusion criteria: - Pacemaker or implantable cardioverter defibrillator (ICD) - Serious blood coagulation disorders that require regular coagulation checks - Abnormalities in the last known ECG - Patients who could avoid observation as part of the study due to other comorbidities not mentioned above
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of measuring WBCs and transmitting data from home (home-based). | — |
Secondary
| Measure | Time frame |
|---|---|
| Feasibility of ECG measurements and data transmission from home. | — |
Countries
Germany
Outcome results
None listed